JP2015527411A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527411A5 JP2015527411A5 JP2015531335A JP2015531335A JP2015527411A5 JP 2015527411 A5 JP2015527411 A5 JP 2015527411A5 JP 2015531335 A JP2015531335 A JP 2015531335A JP 2015531335 A JP2015531335 A JP 2015531335A JP 2015527411 A5 JP2015527411 A5 JP 2015527411A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- enzalutamide
- weight
- pharmaceutical composition
- solid dispersion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims 14
- 229960004671 enzalutamide Drugs 0.000 claims 12
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000007962 solid dispersion Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 229920002307 Dextran Polymers 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- -1 polyoxyethylene Polymers 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920000855 Fucoidan Polymers 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002292 Nylon 6 Polymers 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 229920001218 Pullulan Polymers 0.000 claims 1
- 239000004373 Pullulan Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 150000005215 alkyl ethers Chemical class 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 229920001727 cellulose butyrate Polymers 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960002086 dextran Drugs 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 229940043138 pentosan polysulfate Drugs 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229940074982 poly(vinylpyrrolidone-co-vinyl-acetate) Drugs 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 235000019423 pullulan Nutrition 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699351P | 2012-09-11 | 2012-09-11 | |
| US61/699,351 | 2012-09-11 | ||
| PCT/US2013/059223 WO2014043208A1 (en) | 2012-09-11 | 2013-09-11 | Formulations of enzalutamide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016176557A Division JP2016204392A (ja) | 2012-09-11 | 2016-09-09 | エンザルタミドの製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527411A JP2015527411A (ja) | 2015-09-17 |
| JP2015527411A5 true JP2015527411A5 (https=) | 2016-11-04 |
| JP6404217B2 JP6404217B2 (ja) | 2018-10-10 |
Family
ID=49231627
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531335A Active JP6404217B2 (ja) | 2012-09-11 | 2013-09-11 | エンザルタミドの製剤 |
| JP2016176557A Pending JP2016204392A (ja) | 2012-09-11 | 2016-09-09 | エンザルタミドの製剤 |
| JP2018011759A Pending JP2018087206A (ja) | 2012-09-11 | 2018-01-26 | エンザルタミドの製剤 |
| JP2019146714A Active JP6932746B2 (ja) | 2012-09-11 | 2019-08-08 | エンザルタミドの製剤 |
| JP2021132868A Pending JP2021178871A (ja) | 2012-09-11 | 2021-08-17 | エンザルタミドの製剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016176557A Pending JP2016204392A (ja) | 2012-09-11 | 2016-09-09 | エンザルタミドの製剤 |
| JP2018011759A Pending JP2018087206A (ja) | 2012-09-11 | 2018-01-26 | エンザルタミドの製剤 |
| JP2019146714A Active JP6932746B2 (ja) | 2012-09-11 | 2019-08-08 | エンザルタミドの製剤 |
| JP2021132868A Pending JP2021178871A (ja) | 2012-09-11 | 2021-08-17 | エンザルタミドの製剤 |
Country Status (30)
| Country | Link |
|---|---|
| US (11) | US20140100256A1 (https=) |
| EP (6) | EP2895463A1 (https=) |
| JP (5) | JP6404217B2 (https=) |
| KR (1) | KR102225416B1 (https=) |
| CN (2) | CN109897004A (https=) |
| AU (2) | AU2013315619B2 (https=) |
| BR (1) | BR112015005432B1 (https=) |
| CA (1) | CA2884795C (https=) |
| CY (1) | CY1124729T1 (https=) |
| DK (1) | DK3725778T4 (https=) |
| EA (2) | EA033374B9 (https=) |
| ES (1) | ES2892029T5 (https=) |
| FI (1) | FI3725778T4 (https=) |
| HK (1) | HK1212701A1 (https=) |
| HR (1) | HRP20211423T4 (https=) |
| HU (1) | HUE057701T2 (https=) |
| IL (1) | IL237604B (https=) |
| IN (1) | IN2015DN02875A (https=) |
| LT (1) | LT3725778T (https=) |
| MX (3) | MX363974B (https=) |
| PH (1) | PH12015500525A1 (https=) |
| PL (1) | PL3725778T5 (https=) |
| PT (1) | PT3725778T (https=) |
| RS (1) | RS62676B2 (https=) |
| SI (1) | SI3725778T1 (https=) |
| SM (1) | SMT202100550T1 (https=) |
| TW (1) | TWI673051B (https=) |
| UA (1) | UA117353C2 (https=) |
| WO (1) | WO2014043208A1 (https=) |
| ZA (1) | ZA201501847B (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6404217B2 (ja) | 2012-09-11 | 2018-10-10 | メディベイション プロステイト セラピューティクス エルエルシー | エンザルタミドの製剤 |
| NZ744456A (en) | 2012-09-26 | 2019-09-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| CN105377299B (zh) * | 2013-04-17 | 2018-06-12 | 西格诺药品有限公司 | 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法 |
| WO2015118015A1 (en) * | 2014-02-05 | 2015-08-13 | Lek Pharmaceuticals D.D. | Solid pharmaceutical compositions of androgen receptor antagonists |
| CN104356068A (zh) * | 2014-10-30 | 2015-02-18 | 杭州新博思生物医药有限公司 | 恩杂鲁胺新晶型及其制备方法 |
| LT3226842T (lt) * | 2014-12-05 | 2021-03-25 | Aragon Pharmaceuticals, Inc. | Priešvėžinės kompozicijos |
| SG11201704267VA (en) | 2014-12-05 | 2017-06-29 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| HUE054935T2 (hu) * | 2014-12-05 | 2021-10-28 | Aragon Pharmaceuticals Inc | Rákellenes készítmények |
| CN104546714A (zh) * | 2015-02-11 | 2015-04-29 | 江苏慧博生物科技有限公司 | 一种恩杂鲁胺胶束制剂及其制备方法 |
| US20180022819A1 (en) * | 2015-02-11 | 2018-01-25 | Aptevo Research And Development Llc | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins |
| CN104857517B (zh) * | 2015-05-14 | 2018-04-27 | 南京海纳医药科技股份有限公司 | 一种恩杂鲁胺软胶囊及其制备方法 |
| ES3063790T3 (en) | 2015-06-09 | 2026-04-20 | Lonza Sales Ag | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| CN105030685B (zh) * | 2015-07-21 | 2018-02-27 | 福格森（武汉）生物科技股份有限公司 | 一种恩杂鲁胺固体分散体口服制剂 |
| WO2017027665A1 (en) | 2015-08-12 | 2017-02-16 | Medivation Prostate Therapeutics, Inc. | Treatment of cancer using a combination of enzalutamide and a cyp3a4 inducer |
| WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| ES3008933T3 (en) | 2015-09-29 | 2025-03-25 | Merz Pharmaceuticals Llc | Sustained release compositions of 4-aminopyridine |
| CN107126419B (zh) * | 2016-02-26 | 2020-06-19 | 石药集团中诺药业（石家庄）有限公司 | 一种奥贝胆酸片剂及其制备方法 |
| US11478453B2 (en) | 2016-07-21 | 2022-10-25 | Hadasit Medical Research Services And Development Ltd. | Treatment for glioblastoma |
| CA3036011A1 (en) | 2016-08-20 | 2018-03-01 | Ftf Pharma Private Limited | Pharmaceutical composition comprising an androgen receptor inhibitor |
| KR102640668B1 (ko) * | 2017-04-13 | 2024-02-23 | 장 폴 레몬 | 잔토휴몰-계 조성물 |
| JP7172997B2 (ja) * | 2017-04-28 | 2022-11-16 | アステラス製薬株式会社 | エンザルタミドを含有する経口投与用医薬組成物 |
| TWI787284B (zh) | 2017-06-22 | 2022-12-21 | 美商西建公司 | 以b型肝炎病毒感染表徵之肝細胞癌之治療 |
| WO2019016747A1 (en) * | 2017-07-20 | 2019-01-24 | Dr. Reddy's Laboratories Limited | AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION |
| BR112020002705A2 (pt) * | 2017-08-08 | 2020-07-28 | Dr. Reddys Laboratories Limited | composições extrudadas de enzalutamida |
| US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| WO2019155416A2 (en) * | 2018-02-09 | 2019-08-15 | Kashiv Pharma Llc | A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens |
| ES2967689T3 (es) * | 2018-04-06 | 2024-05-03 | Capsugel Belgium Nv | Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)] |
| CZ2018234A3 (cs) | 2018-05-21 | 2019-12-04 | Zentiva Ks | Zvýšení rozpustnosti a biodostupnosti enzalutamidu |
| CN112955130A (zh) * | 2018-10-30 | 2021-06-11 | 佩洛通治疗公司 | 包含取代茚满的固体分散体和药物组合物及其制备和使用方法 |
| WO2020122244A1 (ja) * | 2018-12-14 | 2020-06-18 | 富士フイルム株式会社 | 錠剤及びその製造方法 |
| CN109432016B (zh) * | 2018-12-26 | 2021-03-02 | 广州中医药大学(广州中医药研究院) | 一种恩杂鲁胺的三元固体制剂及其制备方法 |
| WO2020144650A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of prostate cancer |
| EP3917519A1 (en) | 2019-01-30 | 2021-12-08 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| KR20210122275A (ko) | 2019-01-30 | 2021-10-08 | 얀센 파마슈티카 엔.브이. | 분자 아형에 기초하여 전립선암을 치료하는 방법 |
| CA3139380A1 (en) | 2019-05-16 | 2020-11-19 | Leon-Nanodrugs Gmbh | Method for producing nanoparticles |
| CA3141534A1 (en) | 2019-05-23 | 2020-11-26 | Helm Ag | Nanoparticles comprising enzalutamide |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| US20220242829A1 (en) | 2019-06-27 | 2022-08-04 | Synthon B.V. | Process for preparation of enzalutamide |
| JP7812785B2 (ja) * | 2019-09-18 | 2026-02-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害薬の剤形 |
| CA3149182A1 (en) * | 2019-09-23 | 2021-04-01 | Bionomics Limited | Therapeutic formulations and uses thereof |
| WO2021064123A1 (en) | 2019-10-03 | 2021-04-08 | Synthon B.V. | Pharmaceutical composition comprising enzalutamide |
| US11723898B2 (en) | 2019-11-04 | 2023-08-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| IL297939A (en) * | 2020-05-06 | 2023-01-01 | Disruptive Pharma Ab | New amorphous active pharmaceutical ingredients |
| AR118925A1 (es) * | 2020-05-13 | 2021-11-10 | Novocap S A | Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución |
| WO2021240206A1 (en) | 2020-05-24 | 2021-12-02 | Lotus International Pte. Ltd. | Enzalutamide formulation |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| CN114053243B (zh) * | 2020-08-05 | 2024-11-12 | 齐鲁制药有限公司 | 一种恩扎卢胺软胶囊及其制备方法 |
| WO2022049523A1 (en) | 2020-09-04 | 2022-03-10 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| CA3191084A1 (en) * | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
| IL301389A (en) * | 2020-09-18 | 2023-05-01 | Bristol Myers Squibb Co | Dosage forms for tyk2 inhibitors comprising swellable cores |
| CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| BR112023022789A2 (pt) | 2021-07-07 | 2024-02-27 | Bdr Pharmaceuticals International Private Ltd | Composição farmacêutica na forma de uma solução oral de enzalutamida, composição farmacêutica na forma de uma solução oral de enzalutamida e método para preparar uma solução oral de enzalutamida |
| CN115721612B (zh) * | 2021-08-26 | 2024-07-26 | 上海宣泰医药科技股份有限公司 | 一种恩扎卢胺固体制剂颗粒及其制备方法 |
| CN118251213A (zh) * | 2022-01-19 | 2024-06-25 | 四川科伦药物研究院有限公司 | 固体分散体及其制备方法和包含其的药物组合物 |
| CN114224832A (zh) * | 2022-02-11 | 2022-03-25 | 明度智云(浙江)科技有限公司 | 一种恩杂鲁胺注射剂及其制备方法和应用 |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| WO2023244617A1 (en) * | 2022-06-13 | 2023-12-21 | Virginia Polytechnic Institute And State University | Amphiphilic cellulose derivatives, methods of making, and uses thereof |
| TW202416960A (zh) * | 2022-06-17 | 2024-05-01 | 美商特朗奎斯治療股份有限公司 | 2-芳基苯并咪唑化合物之調配物 |
| CN115887395A (zh) * | 2022-11-18 | 2023-04-04 | 上海药坦药物研究开发有限公司 | 恩杂鲁胺固体分散体制剂及其制备方法和应用 |
| EP4374853A1 (en) | 2022-11-22 | 2024-05-29 | Lotus Pharmaceutical Co., Ltd. | Solid formulation of enzalutamide |
| WO2024153733A1 (en) | 2023-01-18 | 2024-07-25 | Helm Ag | Crystalline nanoparticles comprising enzalutamide |
| WO2024191660A2 (en) * | 2023-03-10 | 2024-09-19 | Yale University | Compositions and methods for treating steroid hormone-related diseases or disorders |
| CN121038790A (zh) | 2023-03-16 | 2025-11-28 | 拜耳消费者护理股份有限公司 | 用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂 |
| WO2025052925A1 (ja) * | 2023-09-08 | 2025-03-13 | 沢井製薬株式会社 | エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法 |
| KR20250058470A (ko) | 2023-10-23 | 2025-04-30 | 케이원팜 주식회사 | 안정성과 용출특성이 향상된 신규 엔잘루타마이드 함유 조성물 및 이의 제조방법 |
| EP4520322A1 (en) * | 2023-12-06 | 2025-03-12 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical compositions containing enzalutamide |
| WO2025125565A1 (en) | 2023-12-13 | 2025-06-19 | Krka, D.D., Novo Mesto | Tablet comprising enzalutamide |
| KR20250100928A (ko) | 2023-12-27 | 2025-07-04 | 케이원팜 주식회사 | 생체이용률이 개선된 엔잘루타마이드 약학 조성물 및 이의 제조방법 |
| CN118001243B (zh) * | 2024-01-31 | 2024-10-22 | 四川鲁徽制药有限责任公司 | 一种恩杂鲁胺口腔崩解片及其制备方法 |
| TR2024004340A1 (tr) * | 2024-04-05 | 2025-10-21 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Enzalutamidin katı dispersiyonu. |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656651A (en) * | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| EP1741424B1 (en) | 1997-08-11 | 2018-10-03 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailabilty |
| ES2287971T3 (es) † | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
| IN191496B (https=) | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
| PE20011184A1 (es) | 2000-03-16 | 2001-11-15 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
| CZ20032225A3 (cs) | 2001-02-27 | 2003-11-12 | Astrazeneca Ab | Farmaceutická formulace |
| SE0103424D0 (sv) † | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| GB2383042A (en) * | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
| SE0103839D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
| BR0307515A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
| JP2005523360A (ja) * | 2002-04-18 | 2005-08-04 | アベシア・リミテッド | 共役分子の製造および製造において使用するための物質 |
| JP4249950B2 (ja) | 2002-06-28 | 2009-04-08 | 富士フイルム株式会社 | 紙管切断装置及び紙管切断方法 |
| AU2003209667A1 (en) * | 2003-02-21 | 2004-09-09 | Hetero Drugs Limited | Bicalutamide polymorphs |
| EP1730516A1 (en) | 2004-03-30 | 2006-12-13 | Pfizer Products Incorporated | Method and device for evaluation of pharmaceutical compositions |
| NZ564223A (en) * | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| US7709517B2 (en) * | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| WO2006123223A1 (en) | 2005-05-19 | 2006-11-23 | Pfizer Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| US20070026073A1 (en) | 2005-07-28 | 2007-02-01 | Doney John A | Amorphous efavirenz and the production thereof |
| SI2656842T1 (sl) | 2006-03-27 | 2016-10-28 | The Regents Of The University Of California | Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji |
| US8613946B2 (en) | 2006-12-21 | 2013-12-24 | Isp Investment Inc. | Carotenoids of enhanced bioavailability |
| WO2008110534A1 (en) | 2007-03-13 | 2008-09-18 | Sandoz Ag | Pharmaceutical compositions of poorly soluble drugs |
| CN102083467B (zh) | 2008-03-11 | 2013-12-25 | Aska制药株式会社 | 固体分散体及其药物组合物、以及它们的制备方法 |
| MY172424A (en) † | 2009-04-03 | 2019-11-25 | Hoffmann La Roche | Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof |
| US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| DK2538785T3 (en) * | 2010-02-24 | 2018-05-22 | Medivation Prostate Therapeutics Llc | Methods for the synthesis of diarylthiohydantoin and diarylhydantoin compounds |
| NZ602288A (en) * | 2010-03-10 | 2014-02-28 | Abbvie Bahamas Ltd | Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| EP2858985B1 (en) | 2012-06-07 | 2018-04-18 | Aragon Pharmaceuticals, Inc. | Crystalline forms of an androgen receptor modulator |
| US9515365B2 (en) * | 2012-08-10 | 2016-12-06 | Keyssa, Inc. | Dielectric coupling systems for EHF communications |
| KR20150053963A (ko) | 2012-09-11 | 2015-05-19 | 닥터 레디스 레보러터리즈 리미티드 | 엔잘루타마이드 다형태 및 그의 제조 |
| JP6404217B2 (ja) | 2012-09-11 | 2018-10-10 | メディベイション プロステイト セラピューティクス エルエルシー | エンザルタミドの製剤 |
| EP2895150A1 (en) | 2012-09-11 | 2015-07-22 | Bend Research, Inc. | Methods for making pharmaceutical solid dosage forms of spray-dried dispersions |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| JP7172997B2 (ja) | 2017-04-28 | 2022-11-16 | アステラス製薬株式会社 | エンザルタミドを含有する経口投与用医薬組成物 |
| US20190208236A1 (en) | 2018-01-02 | 2019-07-04 | Source Digital, Inc. | Coordinates as ancillary data |
| WO2021064123A1 (en) | 2019-10-03 | 2021-04-08 | Synthon B.V. | Pharmaceutical composition comprising enzalutamide |
-
2013
- 2013-09-11 JP JP2015531335A patent/JP6404217B2/ja active Active
- 2013-09-11 EA EA201500314A patent/EA033374B9/ru not_active IP Right Cessation
- 2013-09-11 TW TW102132800A patent/TWI673051B/zh active
- 2013-09-11 CA CA2884795A patent/CA2884795C/en active Active
- 2013-09-11 EP EP13766437.1A patent/EP2895463A1/en not_active Withdrawn
- 2013-09-11 HR HRP20211423TT patent/HRP20211423T4/hr unknown
- 2013-09-11 CN CN201811517651.2A patent/CN109897004A/zh active Pending
- 2013-09-11 SM SM20210550T patent/SMT202100550T1/it unknown
- 2013-09-11 BR BR112015005432-3A patent/BR112015005432B1/pt active IP Right Grant
- 2013-09-11 ES ES20177837T patent/ES2892029T5/es active Active
- 2013-09-11 CN CN201380055471.6A patent/CN105358535B/zh active Active
- 2013-09-11 EP EP21190086.5A patent/EP3971167A1/en not_active Withdrawn
- 2013-09-11 LT LTEP20177837.0T patent/LT3725778T/lt unknown
- 2013-09-11 AU AU2013315619A patent/AU2013315619B2/en active Active
- 2013-09-11 EP EP20177837.0A patent/EP3725778B2/en active Active
- 2013-09-11 DK DK20177837.0T patent/DK3725778T4/da active
- 2013-09-11 EP EP24198653.8A patent/EP4450130A3/en active Pending
- 2013-09-11 KR KR1020157009040A patent/KR102225416B1/ko active Active
- 2013-09-11 US US14/023,637 patent/US20140100256A1/en not_active Abandoned
- 2013-09-11 WO PCT/US2013/059223 patent/WO2014043208A1/en not_active Ceased
- 2013-09-11 HK HK16100714.7A patent/HK1212701A1/zh unknown
- 2013-09-11 FI FIEP20177837.0T patent/FI3725778T4/fi active
- 2013-09-11 SI SI201331927T patent/SI3725778T1/sl unknown
- 2013-09-11 UA UAA201503119A patent/UA117353C2/uk unknown
- 2013-09-11 PL PL20177837.0T patent/PL3725778T5/pl unknown
- 2013-09-11 EA EA201991484A patent/EA201991484A1/ru unknown
- 2013-09-11 HU HUE20177837A patent/HUE057701T2/hu unknown
- 2013-09-11 RS RS20211117A patent/RS62676B2/sr unknown
- 2013-09-11 PT PT201778370T patent/PT3725778T/pt unknown
- 2013-09-11 IN IN2875DEN2015 patent/IN2015DN02875A/en unknown
- 2013-09-11 MX MX2015003140A patent/MX363974B/es active IP Right Grant
- 2013-09-11 EP EP23205739.8A patent/EP4324527A3/en not_active Withdrawn
- 2013-09-11 EP EP22197255.7A patent/EP4169908A1/en not_active Withdrawn
- 2013-09-11 US US14/023,878 patent/US20140179749A1/en not_active Abandoned
-
2014
- 2014-09-10 US US14/481,986 patent/US20140378517A1/en not_active Abandoned
-
2015
- 2015-03-08 IL IL237604A patent/IL237604B/en unknown
- 2015-03-11 MX MX2019003984A patent/MX2019003984A/es unknown
- 2015-03-11 MX MX2021000007A patent/MX2021000007A/es unknown
- 2015-03-11 PH PH12015500525A patent/PH12015500525A1/en unknown
- 2015-03-18 ZA ZA2015/01847A patent/ZA201501847B/en unknown
-
2016
- 2016-02-08 US US15/018,078 patent/US20170027910A1/en not_active Abandoned
- 2016-09-09 JP JP2016176557A patent/JP2016204392A/ja active Pending
- 2016-09-16 US US15/267,352 patent/US20170224624A1/en not_active Abandoned
-
2018
- 2018-01-15 AU AU2018200316A patent/AU2018200316A1/en not_active Abandoned
- 2018-01-26 JP JP2018011759A patent/JP2018087206A/ja active Pending
- 2018-07-24 US US16/044,255 patent/US20190209476A1/en not_active Abandoned
-
2019
- 2019-04-01 US US16/371,618 patent/US20200060976A1/en not_active Abandoned
- 2019-08-08 JP JP2019146714A patent/JP6932746B2/ja active Active
-
2021
- 2021-08-17 JP JP2021132868A patent/JP2021178871A/ja active Pending
- 2021-09-14 CY CY20211100809T patent/CY1124729T1/el unknown
-
2022
- 2022-11-11 US US17/985,220 patent/US12447128B2/en active Active
- 2022-11-11 US US17/985,235 patent/US11839689B2/en active Active
-
2024
- 2024-10-30 US US18/931,464 patent/US20250049721A1/en active Pending
- 2024-12-04 US US18/967,829 patent/US12502357B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015527411A5 (https=) | ||
| JP2012236837A5 (https=) | ||
| NZ605232A (en) | Formulations of rifaximin and uses thereof | |
| JP2016539953A5 (https=) | ||
| JP2017511344A5 (https=) | ||
| JP2015527395A5 (https=) | ||
| FI2346495T4 (fi) | Farmaseuttinen formulaatio 514 | |
| JP2013529637A5 (https=) | ||
| JP2013103899A (ja) | 難溶性薬物の新規な固体分散体 | |
| JP2012025755A5 (https=) | ||
| RU2012157685A (ru) | Твердая дисперсия толваптана и способ ее получения | |
| JP2014167026A5 (https=) | ||
| RU2016151163A (ru) | Композиции, включающие электрогидродинамически полученные волокна, для нанесения заданных доз активного вещества на кожу или слизистую оболочку | |
| JP2017536398A5 (https=) | ||
| JP2012508172A5 (https=) | ||
| JP2007517016A5 (https=) | ||
| JP2017536401A5 (https=) | ||
| CN106255496A (zh) | 包括紫杉烷的无定形固体分散体、包括其的片剂以及用于制备其的方法 | |
| RU2016101760A (ru) | Высокоэффективные фармацевтические композиции панкреатина | |
| Zhang et al. | Study on the effect of polymer excipients on the dispersibility, interaction, solubility, and scavenging reactive oxygen species of myricetin solid dispersion: experiment and molecular simulation | |
| JP2015515968A5 (https=) | ||
| JP2014520871A5 (https=) | ||
| JP2017523149A5 (https=) | ||
| CN102793706A (zh) | 托伐普坦固体分散体的制备方法 | |
| TW201601719A (zh) | 阿利沙坦酯固體分散體及含有該固體分散體的藥物組合物 |